Stereotaxis Inc is primarily active in the healthcare industry.

The main competitors of Stereotaxis Inc in the market include XYZ Corporation, ABC Corporation, and LMN Corporation.

Stereotaxis Inc is a leading healthcare technology company specializing in robotic surgical systems. Founded in 1990, Stereotaxis has transformed the field of electrophysiology by developing and commercializing innovative robotic platforms. The company's proprietary technology enables physicians to perform precise and minimally invasive procedures, improving patient outcomes. Stereotaxis' versatile robotic systems, including the Niobe® Magnetic Navigation System, have gained recognition for their exceptional precision and safety. With a strong commitment to technological advancements, Stereotaxis Inc continues to revolutionize the medical industry, providing healthcare professionals with cutting-edge tools for improved patient care.

Stereotaxis Inc has achieved several significant milestones since its inception. Notably, the company revolutionized the field of robotic navigation in healthcare by developing the world's first robotic magnetic navigation system. This pioneering technology, known as the Niobe system, enables precise control and navigation of catheters during minimally invasive procedures. Stereotaxis Inc has also successfully expanded its global presence, with installations of the Niobe system in leading hospitals worldwide. Additionally, the company has consistently demonstrated its commitment to innovation, regularly enhancing its platform with advanced features and software updates. These accomplishments have solidified Stereotaxis Inc as a leading player in the field of robotic-assisted healthcare navigation.

Stereotaxis Inc is primarily present in the United States.

Stereotaxis Inc represents values of innovation, precision, and patient-centered care. This medical technology company is committed to revolutionizing the field of surgical robotics, particularly in the area of cardiac care. Their corporate philosophy focuses on enhancing clinical outcomes, reducing procedure time, and improving patient safety through their advanced robotic navigation systems. Stereotaxis Inc aims to provide healthcare professionals with cutting-edge tools that enable minimally invasive procedures and precise, personalized treatments. By harnessing the power of technology and research, Stereotaxis Inc strives to elevate the standard of care for patients worldwide.

Analysts currently set an average price target of 4,28 USD for the Stereotaxis stock (median: 4,08 USD), implying +215,0 % versus the latest price. The consensus is based on 11 analyst ratings.

Stereotaxis Analyytikkojen kursstavoitteet 2026

11 analysts currently rate the Stereotaxis stock: 10 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Stereotaxis to generate revenue of 39,40 M USD and earnings per share of −0,17 USD.

Stereotaxis Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Stereotaxis share trades at 1,18 EUR (1,36 USD).

The Stereotaxis share (STXS) is listed on 3 stock exchanges, including: Frankfurt (RJR1.F), München (RJR1.MU).

The company Stereotaxis Inc has developed an innovative business model that revolutionizes the diagnosis and treatment of heart diseases. The company is a leader in the development of technologies for magnetic catheter treatment, a minimally invasive method for treating heart diseases. Stereotaxis is a global company based in the USA and operates in Europe, Asia, and Australia. The company develops and produces magnetic catheter systems used by cardiologists to treat heart diseases in patients. Stereotaxis' magnetic catheter technology enables precise navigation through the body using an electric magnetic field. The application can be done minimally invasively without surgery. The technology consists of a catheter controlled by a computer. The doctor navigates the catheter using a magnetic field and visualizes the position of the catheter on a screen. Stereotaxis' flagship product is the "Niobe" magnetic catheter system. The system consists of various components, including a computer, a console, a control unit, sensors, catheters, and accessories. The Niobe system has been approved by the US Food and Drug Administration (FDA) and is used by cardiologists worldwide. In addition to selling magnetic catheter systems for the treatment of heart diseases, Stereotaxis also offers services such as the management of magnetic catheter labs. The company provides installation and training services for doctors and medical personnel to ensure effective use of the system. Stereotaxis is not only a hardware provider but also a provider of imaging and diagnostic software. Their "Odyssey" system provides a comprehensive platform for processing patient data and integrating medical devices. Odyssey enables better real-time collaboration among medical personnel and provides opportunities for data analysis. Stereotaxis operates a product focused on data collection and analysis, "Vdrive". Vdrive is a wireless and user-friendly instrument for documenting and recording information during invasive cardiology procedures by medical personnel. It enables the management of patient and procedure data, workflow optimization, and quality management. In addition, Stereotaxis offers a comprehensive fleet of service technicians. Operating globally, it provides 24/7 maintenance and support for the technical equipment in cardiology laboratories. Stereotaxis also has a dedicated marketing department for its customers, which organizes symposia, workshops, and conferences among other activities. Overall, Stereotaxis offers a comprehensive range of products and services for magnetic catheter treatment. With their latest innovations in mixed reality technology and zebra MRI system, the company will continue to conduct groundbreaking research and push the boundaries of medical science.

odotettu liikevaihto Stereotaxis on 39,40 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Stereotaxis on −16,40 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Stereotaxis:n hinta-voitto-suhde (P/E) on tällä hetkellä −7,96. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Stereotaxis-osakkeen arvostusta.

Stereotaxis:n hinta-myynti-suhde (P/S) on tällä hetkellä 3,31. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Stereotaxis-osakkeen arvostuskennuslukuna.

Stereotaxis:n Eulpool-laatuscore on 2/10.

Stereotaxis:n ISIN on US85916J4094. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Stereotaxis:n WKN on A1J09L. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Stereotaxis:n ticker on STXS. Tämä pörssinoteeraus käytetään Stereotaxis-osakkeiden kauppaan pörssissä.

Stereotaxis maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Stereotaxis kuuluu sektoriin 'Terveydenhuolto'.

Stereotaxis:n osingot jaetaan valuutassa USD.